Please ensure Javascript is enabled for purposes of website accessibility

These 2 Vaccine Stocks Are Bargains Right Now

By Adria Cimino and Corinne Cardina - Apr 4, 2021 at 8:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Both could play important roles in the future vaccine landscape.

In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss two stocks that have lost more than 40% from February highs -- and why they may make good buys today.

Corinne Cardina: Let's talk about stocks to buy. Given the recent market volatility, are there any vaccine stocks that you would say are a good deal right now?

Adria Cimino: Yes. I would say, there are two. Novavax (NVAX -0.77%) is down 44% from a February high and Vaxart (VXRT 1.28%) is down 73% from a February high. Novavax is the less risky of the two. It had good trial data so far, there's reason to be optimistic about Emergency Use Authorization, and that would represent billions in revenue, they also have a flu vaccine that's close to market. I think it's a good buying opportunity. Vaxart is risky. The clinical trial data on their oral vaccine candidate disappointed some investors because it showed no neutralizing antibodies, but it did have strong killer T response, so there was some good immune response in one way. They are going to start a phase 2 trial, so it's one to watch. I'd say for a high-risk investor maybe grab a few shares, otherwise, it's one to just have your eye on.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$47.63 (-0.77%) $0.37
Vaxart, Inc. Stock Quote
Vaxart, Inc.
VXRT
$3.17 (1.28%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.